Mechanisms of cancer metastasis to the bone

Cell Research

Volumn 15, Issue 1, 2005, Pages 57-62

  Yin, Juan Juan ^a   Pollock, Claire B ^a   Kelly, Kathleen ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bone metastases; Cancer; Osteoblastic metastasis; Osteolytic metastasis

Indexed keywords

ANIMAL; BIOLOGICAL MODEL; BONE; BONE TUMOR; HISTOLOGY; HUMAN; METABOLISM; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); OSTEOBLAST; OSTEOCLAST; PATHOLOGY; REVIEW;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOBLASTS; OSTEOCLASTS;

EID: 19644378914     PISSN: 10010602     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cr.7290266     Document Type: Short Survey

References (50)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-93.
2. Clark PE, Torti FM. Prostate cancer and bone metastases: medical treatment. Clin Orthop 2003, 415:8148-57.
3. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350:1655-64.
4. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 1989; 8:98-101.
5. Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 1999; 6:333-47.
6. Vander Griend DJ, Rinker-Schaeffer CW. A new look at an old problem: the survival and organ-specific growth of metastases. Sci STKE 2004; 2004:pe3.
7. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998; 19:18-54.
8. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 2000; 10:159-78.
9. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50-6.
10. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3:537-49.
11. Deutsch A, Resnick D. Eccentric cortical metastases to the skeleton from bronchogenic carcinoma. Radiology 1980; 137:49-52.
12. Hendrix RW, Rogers LF, Davis TM, Jr. Cortical bone metastases. Radiology 1991; 181:409-13.
13. Miric A, Banks M, Allen D, et al. Cortical metastatic lesions of the appendicular skeleton from tumors of known primary origin. J Surg Oncol 1998; 67:255-60.
14. Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 1991; 51:3059-61.
15. Basolo F, Fiore L, Fontanini G, et al. Expression of and response to interleukin 6 (IL6) in human mammary tumors. Cancer Res 1996; 56:3118-22.
16. Blay JY, Schemann S, Favrot MC. Local production of interleukin 6 by renal adenocarcinoma in vivo. J Natl Cancer Inst 1994; 86:238.
17. Tabibzadeh SS, Poubouridis D, May LT, Sehgal PB. Interleukin-6 immunoreactivity in human tumors. Am J Pathol 1989; 135:427-33.
18. Thabard W, Collette M, Mellerin MP, et al. IL-6 upregulates its own receptor on some human myeloma cell lines. Cytokine 2001; 14:352-56.
19. de la Mata J, Uy HL, Guise TA, et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995; 95:2846-52.
20. Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 1990; 144:4226-30.
21. Ono K, Akatsu T, Murakami T, et al. Involvement of cyclooxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 2002; 17:774-81.
22. Pederson L, Winding B, Foged NT, Spelsberg TC, Oursler MJ. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res 1999; 59:5849-55.
23. Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe L. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 2001; 100:18-24.
24. Sapi L. The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp Biol Med (Maywood) 2004; 229:1-11.
25. Yin JJ, Selander K, Chirgwin JM, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103:197-206.
26. George J, Lai FM. Metastatic cervical carcinoma presenting as psoas abscess and osteoblastic and lytic bony metastases. Singapore Med J 1995; 36:224-7.
27. Joffe N, Antonioli DA. Osteoblastic bone metastases secondary to adenocarcinoma of the pancreas. Clin Radiol 1978; 29:41-6.
28. Paling MR, Pope TL. Computed tomography of isolated osteoblastic colon metastases in the bony pelvis. J Comput Tomogr 1988; 12:203-7.
29. Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop 2003; 415 Suppl:S67-74.
30. Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994; 368:703-10.
31. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1:944-9.
32. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003; 100:10954-9.
33. Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996; 56:663-8.
34. Chiao JW, Moonga BS, Yang YM, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000; 83:360-5.
35. Alam AS, Gallagher A, Shankar V, et al. Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption. Endocrinology 1992; 130:3617-24.
36. Lassiter LK, Carducci MA. Endothelin receptor antagonists in the treatment of prostate cancer. Semin Oncol 2003; 30:678-88.
37. Reddi AH. Bone and cartilage differentiation. Curr Opin Genet Dev 1994; 4:737-44.
38. McCarthy TL, Ji C, Chen Y, et al. Runt domain factor (Runx)-dependent effects on CCAAT/ enhancer-binding protein delta expression and activity in osteoblasts. J Biol Chem 2000; 275:21746-53.
39. Thomas BG, Hamdy FC. Bone morphogenetic protein-6: potential mediator of osteoblastic metastases in prostate cancer. Prostate Cancer Prostatic Dis 2000; 3:283-5.
40. Brubaker KD, Corey E, Brown LG, Vessella RL. Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 2004; 91:151-60.
41. Ide H, Yoshida T, Matsumoto N, et al. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 1997; 57:5022-7.
42. Achbarou A, Kaiser S, Tremblay G, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994; 54:2372-7.
43. Rabbani SA, Desjardins J, Bell AW, et al. An ammo-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990; 173:1058-64.
44. Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993; 192:940-7.
45. Yi B, Williams PJ, Niewolna M, Wang Y, and Yoneda T. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 2002; 62:917-23.
46. Oades GM, Coxon J, Colston KW. The potential role of bisphosphonates in prostate cancer. Prostate Cancer Prostatic Dis 2002; 5:264-72.
47. Yonou H, Ochiai A, Goya M, et al. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions. Prostate 2004; 58:406-13.
48. Garnero P, Buchs N, Zekri J, et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000; 82:858-64.
49. Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20 Suppl 2:45-54.
50. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20:3219-24.